Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome
- PMID: 20534533
- PMCID: PMC2895119
- DOI: 10.1073/pnas.1002262107
Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome
Abstract
Fragile X syndrome (FXS), a common inherited form of mental impairment and autism, is caused by transcriptional silencing of the fragile X mental retardation 1 (FMR1) gene. Earlier studies have identified a role for aberrant synaptic plasticity mediated by the metabotropic glutamate receptors (mGluRs) in FXS. However, many of these observations are derived primarily from studies in the hippocampus. The strong emotional symptoms of FXS, on the other hand, are likely to involve the amygdala. Unfortunately, little is known about how exactly FXS affects synaptic function in the amygdala. Here, using whole-cell recordings in brain slices from adult Fmr1 knockout mice, we find mGluR-dependent long-term potentiation to be impaired at thalamic inputs to principal neurons in the lateral amygdala. Consistent with this long-term potentiation deficit, surface expression of the AMPA receptor subunit, GluR1, is reduced in the lateral amygdala of knockout mice. In addition to these postsynaptic deficits, lower presynaptic release was manifested by a decrease in the frequency of spontaneous miniature excitatory postsynaptic currents (mEPSCs), increased paired-pulse ratio, and slower use-dependent block of NMDA receptor currents. Strikingly, pharmacological inactivation of mGluR5 with 2-methyl-6-phenylethynyl-pyridine (MPEP) fails to rescue either the deficit in long-term potentiation or surface GluR1. However, the same acute MPEP treatment reverses the decrease in mEPSC frequency, a finding of potential therapeutic relevance. Therefore, our results suggest that synaptic defects in the amygdala of knockout mice are still amenable to pharmacological interventions against mGluR5, albeit in a manner not envisioned in the original hippocampal framework.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Fig. 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2895119/bin/pnas.1002262107fig01.gif)
![Fig. 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2895119/bin/pnas.1002262107fig02.gif)
![Fig. 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2895119/bin/pnas.1002262107fig03.gif)
![Fig. 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2895119/bin/pnas.1002262107fig04.gif)
![Fig. 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2895119/bin/pnas.1002262107fig05.gif)
Similar articles
-
Age-Dependent Long-Term Potentiation Deficits in the Prefrontal Cortex of the Fmr1 Knockout Mouse Model of Fragile X Syndrome.Cereb Cortex. 2016 May;26(5):2084-2092. doi: 10.1093/cercor/bhv031. Epub 2015 Mar 5. Cereb Cortex. 2016. PMID: 25750254
-
BDNF in fragile X syndrome.Neuropharmacology. 2014 Jan;76 Pt C:729-36. doi: 10.1016/j.neuropharm.2013.05.018. Epub 2013 May 29. Neuropharmacology. 2014. PMID: 23727436 Review.
-
Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome.Biol Psychiatry. 2012 Dec 1;72(11):924-33. doi: 10.1016/j.biopsych.2012.06.008. Epub 2012 Jul 18. Biol Psychiatry. 2012. PMID: 22817866
-
Fragile X syndrome and the amygdala.Curr Opin Neurobiol. 2011 Jun;21(3):509-15. doi: 10.1016/j.conb.2011.04.005. Curr Opin Neurobiol. 2011. PMID: 21555214 Review.
-
Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15537-42. doi: 10.1073/pnas.0707484104. Epub 2007 Sep 19. Proc Natl Acad Sci U S A. 2007. PMID: 17881561 Free PMC article.
Cited by
-
Effects of AFQ056 on language learning in fragile X syndrome.J Clin Invest. 2023 Aug 31;134(5):e171723. doi: 10.1172/JCI171723. J Clin Invest. 2023. PMID: 37651202 Free PMC article. Clinical Trial.
-
Chemogenetic manipulation of astrocyte activity at the synapse- a gateway to manage brain disease.Front Cell Dev Biol. 2023 Jul 18;11:1193130. doi: 10.3389/fcell.2023.1193130. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37534103 Free PMC article. Review.
-
From circuits to behavior: Amygdala dysfunction in fragile X syndrome.Front Integr Neurosci. 2023 Mar 9;17:1128529. doi: 10.3389/fnint.2023.1128529. eCollection 2023. Front Integr Neurosci. 2023. PMID: 36969493 Free PMC article. Review.
-
Impaired AMPARs Translocation into Dendritic Spines with Motor Skill Learning in the Fragile X Mouse Model.eNeuro. 2023 Mar 27;10(3):ENEURO.0364-22.2023. doi: 10.1523/ENEURO.0364-22.2023. Print 2023 Mar. eNeuro. 2023. PMID: 36898833 Free PMC article.
-
Axonal and presynaptic FMRP: Localization, signal, and functional implications.Hear Res. 2023 Mar 15;430:108720. doi: 10.1016/j.heares.2023.108720. Epub 2023 Feb 11. Hear Res. 2023. PMID: 36809742 Free PMC article. Review.
References
-
- Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27:370–377. - PubMed
-
- Ronesi JA, Huber KM. Metabotropic glutamate receptors and fragile X mental retardation protein: Partners in translational regulation at the synapse. Sci Signal. 2008;1:pe6. - PubMed
-
- Hou L, et al. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron. 2006;51:441–454. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases